On August 24, 2026, Globus Medical Inc GMED shares fell 3.3% to a current price of $84.08, positioned within a 52-week range of $54.15 to $101.40. This recent decline marks a year-to-date decrease of 3.7%, despite a strong one-year performance of 34.5%.
- GF Valueâ„¢ verdict: Current price is $84.08, which is 13.1% below the GF Valueâ„¢ of $96.81.
- GF Scoreâ„¢: 95/100, indicating a strong overall company performance.
- Most notable signal: Insiders sold $15.9M worth of shares over the past 12 months, with no buying activity.
Is GMED Overvalued or Undervalued?
With a current price of $84.08 compared to a GF Valueâ„¢ of $96.81, GMED is considered 13.1% undervalued, presenting potential investment opportunities for those assessing intrinsic value. The GF Valueâ„¢ represents GuruFocus' proprietary estimate of intrinsic value, derived from historical trading multiples, business growth patterns, and future performance forecasts. The valuation indicates a margin of safety for prospective investors, suggesting that the stock is trading below its estimated fair value.
The GF Valuation label categorizes GMED as modestly undervalued, implying that there is room for appreciation in the stock price if the company's growth continues as forecasted. However, potential investors should consider the risks involved, particularly given the recent insider selling activity, which may indicate a lack of confidence in future performance.
How Does GMED's Valuation Compare to Its History?
| Metric | Current | Historical |
|---|---|---|
| P/E (TTM) | 21.5x | 40.9x |
| Forward P/E | 16.9x | N/A |
GMED's current P/E ratio of 21.5x is significantly below its 5-year median P/E of 40.9x, suggesting that the stock is trading at a discount compared to its historical valuation. The forward P/E of 16.9x further reinforces the notion that GMED may be undervalued, aligning with the GF Valueâ„¢ assessment. This P/E analysis supports the conclusion that there is potential for price recovery in the future.
What Does GMED's GF Scoreâ„¢ Tell Us?
The GF Scoreâ„¢ evaluates a company's overall performance based on multiple factors including financial strength, profitability, growth, valuation, and momentum. GMED's GF Scoreâ„¢ of 95/100 indicates a strong performance across these dimensions, with its highest scores in profitability and growth, both rated at 9/10, while the valuation rank stands out at 10/10, indicating exceptional valuation metrics. However, the momentum rank at 8/10 shows that while the company has performed well, its recent price movement has not been as robust compared to historical trends.
| Metric | Rating |
|---|---|
| GF Scoreâ„¢ | 95 |
| Financial Strength | 8/10 |
| Profitability | 9/10 |
| Growth | 9/10 |
| Valuation | 10/10 |
| Momentum | 8/10 |
Overall, GMED demonstrates strong financial health and profitability, reflecting its capacity to generate significant returns. The outstanding valuation rank suggests that the stock presents an attractive buying opportunity, albeit the momentum rank indicates caution due to recent share price volatility. The combination of these scores provides a comprehensive view of the company's standing.
What Are Gurus and Insiders Doing with GMED?
Currently, 8 gurus hold GMED shares, with 5 increasing their positions and 4 reducing their stakes in recent quarters. This mixed signal suggests a level of confidence among certain key investors while also indicating caution from others.
On the insider side, there has been significant selling activity, with insiders offloading $15.9M worth of shares over the past year, and notably, there has been no buying activity during this period. This pattern of selling may reflect a lack of confidence in the short-term prospects of the company, contrasting with the positive sentiment expressed by some institutional investors.
What This Means for Investors
Given the current GF Valueâ„¢ assessment of $96.81, GMED is viewed as undervalued, offering potential opportunities for investors looking for fundamentally sound stocks at a discount. However, the insider selling activity and the recent price movements warrant careful consideration. For further insights, visit the Globus Medical Inc GMED stock page, or explore more on the GF Valueâ„¢ page.
Frequently Asked Questions
What is GMED's GF Scoreâ„¢?
GMED has a GF Scoreâ„¢ of 95/100, indicating a strong overall company performance across key financial metrics.
Is GMED overvalued or undervalued?
GMED is currently undervalued with a GF Valueâ„¢ of $96.81, representing a 13.1% margin below its intrinsic value.
What is GMED's P/E ratio?
GMED's P/E (TTM) is 21.5x, which is significantly below its 5-year median of 40.9x, indicating a favorable valuation relative to its historical performance.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
